JPWO2023070082A5 - - Google Patents
Info
- Publication number
- JPWO2023070082A5 JPWO2023070082A5 JP2024523783A JP2024523783A JPWO2023070082A5 JP WO2023070082 A5 JPWO2023070082 A5 JP WO2023070082A5 JP 2024523783 A JP2024523783 A JP 2024523783A JP 2024523783 A JP2024523783 A JP 2024523783A JP WO2023070082 A5 JPWO2023070082 A5 JP WO2023070082A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai agent
- nucleotides
- nucleotide sequence
- sense strand
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163270849P | 2021-10-22 | 2021-10-22 | |
| US63/270,849 | 2021-10-22 | ||
| US202263308289P | 2022-02-09 | 2022-02-09 | |
| US63/308,289 | 2022-02-09 | ||
| US202263345654P | 2022-05-25 | 2022-05-25 | |
| US63/345,654 | 2022-05-25 | ||
| PCT/US2022/078498 WO2023070082A2 (en) | 2021-10-22 | 2022-10-21 | Rnai agents for inhibiting expression of matrix metalloproteinase 7(mmp7), compositions thereof, and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024539193A JP2024539193A (ja) | 2024-10-28 |
| JPWO2023070082A5 true JPWO2023070082A5 (https=) | 2025-10-28 |
| JP2024539193A5 JP2024539193A5 (https=) | 2025-10-28 |
Family
ID=86059695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523783A Pending JP2024539193A (ja) | 2021-10-22 | 2022-10-21 | マトリックスメタロプロテイナーゼ７（ＭＭＰ７）の発現を抑制するためのＲＮＡｉ剤、その組成物、及び使用の方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230265437A1 (https=) |
| EP (1) | EP4419689A2 (https=) |
| JP (1) | JP2024539193A (https=) |
| KR (1) | KR20240099296A (https=) |
| AU (1) | AU2022368927A1 (https=) |
| CA (1) | CA3235224A1 (https=) |
| CL (1) | CL2024001175A1 (https=) |
| CO (1) | CO2024005110A2 (https=) |
| IL (1) | IL312239A (https=) |
| MX (1) | MX2024004912A (https=) |
| PE (1) | PE20241185A1 (https=) |
| TW (1) | TW202334416A (https=) |
| WO (1) | WO2023070082A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024302964A1 (en) * | 2023-06-13 | 2025-12-18 | Tuojie Biotech (Shanghai) Co., Ltd. | Sirna targeting mmp7, sirna conjugate and medical use thereof |
| KR20260046154A (ko) | 2023-07-28 | 2026-04-06 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | siRNA 및 이의 조성물 |
| WO2025152967A1 (zh) * | 2024-01-15 | 2025-07-24 | 武汉人福创新药物研发中心有限公司 | 靶向αvβ6的化合物及其用途 |
| WO2025228156A1 (zh) * | 2024-04-30 | 2025-11-06 | 北京炫景瑞医药科技有限公司 | 肾靶向的双链寡核苷酸缀合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| US20050118625A1 (en) * | 2003-10-02 | 2005-06-02 | Mounts William M. | Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases |
| WO2006092795A2 (en) * | 2005-03-01 | 2006-09-08 | Qbi Enterprises Ltd. | Oligoribonucleotides and methods of use thereof for treatment of ocular scarring and other fibrotic conditions |
| JP7445594B2 (ja) * | 2017-11-01 | 2024-03-07 | アローヘッド ファーマシューティカルズ インコーポレイテッド | インテグリンリガンドおよびその使用 |
| US12372530B2 (en) * | 2017-11-15 | 2025-07-29 | Beth Israel Deaconess Medical Center, Inc. | Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis |
| JP2023541422A (ja) * | 2020-09-11 | 2023-10-02 | アローヘッド ファーマシューティカルズ インコーポレイテッド | インテグリン標的化リガンド及びその使用 |
-
2022
- 2022-10-21 JP JP2024523783A patent/JP2024539193A/ja active Pending
- 2022-10-21 CA CA3235224A patent/CA3235224A1/en active Pending
- 2022-10-21 US US18/048,577 patent/US20230265437A1/en active Pending
- 2022-10-21 KR KR1020247016352A patent/KR20240099296A/ko active Pending
- 2022-10-21 EP EP22884722.4A patent/EP4419689A2/en active Pending
- 2022-10-21 PE PE2024000898A patent/PE20241185A1/es unknown
- 2022-10-21 MX MX2024004912A patent/MX2024004912A/es unknown
- 2022-10-21 IL IL312239A patent/IL312239A/en unknown
- 2022-10-21 AU AU2022368927A patent/AU2022368927A1/en active Pending
- 2022-10-21 WO PCT/US2022/078498 patent/WO2023070082A2/en not_active Ceased
- 2022-10-21 TW TW111140110A patent/TW202334416A/zh unknown
-
2024
- 2024-04-15 CL CL2024001175A patent/CL2024001175A1/es unknown
- 2024-04-23 CO CONC2024/0005110A patent/CO2024005110A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025185070A5 (https=) | ||
| CN108136206B (zh) | 抗乙型肝炎病毒的组合物和药剂及其用途 | |
| JP2020526192A5 (https=) | ||
| JP2020533334A5 (https=) | ||
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2018529732A5 (https=) | ||
| JP7697889B2 (ja) | アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法 | |
| US20230119360A1 (en) | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv | |
| JPWO2020061177A5 (https=) | ||
| CN110832077B (zh) | 用于抑制α-ENaC表达的RNAi剂及使用方法 | |
| JP2008510019A5 (https=) | ||
| JP2023536999A (ja) | Ｂ型肝炎患者のオリゴヌクレオチド処置 | |
| JPWO2022032288A5 (https=) | ||
| JP2024544532A (ja) | Ｈｂｖの処置のための医薬組合せ | |
| JPWO2023070082A5 (https=) | ||
| JP2023506540A (ja) | Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用 | |
| US20230123601A1 (en) | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv | |
| JPWO2021195467A5 (https=) | ||
| JPWO2022216920A5 (https=) | ||
| JP2023541170A (ja) | Ｚ－ａａｔタンパク質のレベルを低下させる方法 | |
| WO2024245424A1 (zh) | 一种用于免疫类疾病的双链核苷酸化合物及其应用 | |
| JP2024026903A (ja) | ｓｉＲＮＡ及び医薬組成物並びに予防及び／又は治療剤 | |
| JPWO2021126734A5 (https=) | ||
| US20260103712A1 (en) | Anti-fibrotic microrna composition | |
| JPWO2023083906A5 (https=) |